Mitchell E. Reff
24Patents
15h-index
13Co-inventors
74Inventor score
Filing activity: Nov 3, 1993 → Apr 9, 2008
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5736137A | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma | Emerging Cross-Sectional Technologies | 708 | Expired |
| US5776456A | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma | Emerging Cross-Sectional Technologies | 279 | Expired |
| US5843439A | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma | Emerging Cross-Sectional Technologies | 145 | Expired |
| US7422739B2 | Anti-CD20 antibodies | Emerging Cross-Sectional Technologies | 138 | Expired |
| US6399061B1 | Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphoma | Emerging Cross-Sectional Technologies | 124 | Expired |
| US6136310A | Recombinant anti-CD4 antibodies for human therapy | Chemistry; Metallurgy | 64 | Expired |
| US6682734B1 | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma | Emerging Cross-Sectional Technologies | 57 | Expired |
| US6159730A | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same | Chemistry; Metallurgy | 50 | Expired |
| US5733779A | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same | Chemistry; Metallurgy | 45 | Expired |
| US5830698A | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same | Chemistry; Metallurgy | 43 | Expired |
| US5648267A | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same | Chemistry; Metallurgy | 37 | Expired |
| US6011138A | Gamma-1 anti-human CD23 monoclonal antibodies | Chemistry; Metallurgy | 32 | Expired |
| US7033589B1 | γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics | Chemistry; Metallurgy | 28 | Expired |
| US7381560B2 | Expression and use of anti-CD20 antibodies | Emerging Cross-Sectional Technologies | 22 | Expired |
| US7744877B2 | Expression and use of anti-CD20 Antibodies | Emerging Cross-Sectional Technologies | 18 | Active |
| US8603473B2 | Modified binding molecules comprising connecting peptides | Chemistry; Metallurgy | 13 | Active |
| US7338658B2 | Recombinant anti-CD4 antibodies for human therapy | Chemistry; Metallurgy | 12 | Expired |
| US6017733A | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same | Chemistry; Metallurgy | 8 | Expired |
| US6893636B2 | Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics | Chemistry; Metallurgy | 5 | Expired |
| US7452534B1 | Recombinant anti-CD4 antibodies for human therapy | Chemistry; Metallurgy | 3 | Expired |
| US7223392B2 | Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics | Chemistry; Metallurgy | 2 | Expired |
| US7332163B2 | Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics | Chemistry; Metallurgy | 1 | Expired |
| US7438906B2 | Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics | Chemistry; Metallurgy | 1 | Expired |
| US7695940B2 | Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.